Reported Earlier, BeiGene Highlights Long-Term BRUKINSA Efficacy And Pipeline Innovations For CLL At ASH 2024
0.15 billion! Wuxi AppTec invested in a French VC, adding to the European biomedical market.
① Wuxi Apptec plans to invest in the "Jeito II S.L.P." fund, with a total target scale not exceeding 1.2 billion euros, and the fund is expected to invest in 14-17 medical innovative startups. ② Previously, Wuxi Apptec planned to invest 10 million euros in another well-known biotechnology investment institution in Europe, focusing on early-stage biomedical companies in Europe.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
BeiGene Started at Overweight at Morgan Stanley on Brukinsa Market Share Growth
Morgan Stanley Assumes BeiGene at Overweight, Announces Price Target of $300
Why Is BeiGene Stock Trading Higher On Wednesday?